FLIR announced this week it has been awarded the first option phase on a five-year, cost-plus fixed fee contract by the United States Department of Defense’s Defense Threat Reduction Agency (DTRA). This option totals $1.2 million for continued development of the FLIR Agentase C2 chemical agent disclosure spray (ADS) for detection of nerve agents and a new formulation for fentanyl detection.
The FLIR Agentase C2 product line is used to visualize chemical threats on hardened military equipment (HME) for verification that trace amounts of chemicals have been decontaminated, and can also be used to map contamination when responding to clandestine labs and other chemical incidents. It provides the capability to rapidly detect trace quantities of toxic, dangerous chemical threats, such as nerve agents and fentanyl variants, for safe and efficient mission performance. Under the contract, FLIR will demonstrate the benefits of electrostatic spraying technology and a new low-light additive on the operational utility of the existing nerve agent formulation.
The timeframe for the first option phase is from August 15, 2018 through August 14, 2019, with three additional option years to follow. Work performed under this contract will take place at the FLIR Pittsburgh, Pa. facility.
For more information about the Agentase C2 spray, visit FLIR.com/Agentase-C2.